Ambalal Sarabhai Enterprises Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 31.33 as of 05 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Krebs Biochemicals & Industries Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 240 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 131 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd?

As of May 5, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.33. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹60.79.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.